JP2014515371A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014515371A5 JP2014515371A5 JP2014512126A JP2014512126A JP2014515371A5 JP 2014515371 A5 JP2014515371 A5 JP 2014515371A5 JP 2014512126 A JP2014512126 A JP 2014512126A JP 2014512126 A JP2014512126 A JP 2014512126A JP 2014515371 A5 JP2014515371 A5 JP 2014515371A5
- Authority
- JP
- Japan
- Prior art keywords
- weight percent
- sucrose
- solid
- preparation
- trehalose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DYNMYYRPPFVAKR-CWXHRMTKSA-N surotomycin Chemical compound C1=CC(CCCCC)=CC=C1C(\C)=C\C(=O)N[C@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]1C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)C=2C(=CC=CC=2)N)C(=O)O[C@@H]1C)[C@H](C)CC(O)=O)=O)CC1=CNC2=CC=CC=C12 DYNMYYRPPFVAKR-CWXHRMTKSA-N 0.000 claims description 117
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 47
- 229930006000 Sucrose Natural products 0.000 claims description 47
- 239000005720 sucrose Substances 0.000 claims description 47
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 33
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 33
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 33
- 238000002360 preparation method Methods 0.000 claims description 26
- 239000007787 solid Substances 0.000 claims description 26
- 239000007864 aqueous solution Substances 0.000 claims description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 11
- 239000007921 spray Substances 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000000377 silicon dioxide Substances 0.000 claims description 6
- 235000012239 silicon dioxide Nutrition 0.000 claims description 6
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 5
- 229920002307 Dextran Polymers 0.000 claims description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 5
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 5
- 238000001694 spray drying Methods 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000006186 oral dosage form Substances 0.000 claims 3
- 239000000463 material Substances 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims 1
- 238000003475 lamination Methods 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000002552 dosage form Substances 0.000 description 97
- 239000012535 impurity Substances 0.000 description 24
- 238000003109 Karl Fischer titration Methods 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 230000000052 comparative effect Effects 0.000 description 15
- 239000000843 powder Substances 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000000087 stabilizing effect Effects 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- -1 anhydro-CB-183 Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161490584P | 2011-05-26 | 2011-05-26 | |
| US61/490,584 | 2011-05-26 | ||
| PCT/US2012/039476 WO2012162567A1 (en) | 2011-05-26 | 2012-05-24 | Cb-183,315 compositions and related methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014515371A JP2014515371A (ja) | 2014-06-30 |
| JP2014515371A5 true JP2014515371A5 (https=) | 2015-07-09 |
Family
ID=46208839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014512126A Pending JP2014515371A (ja) | 2011-05-26 | 2012-05-24 | Ｃｂ−１８３，３１５組成物および関連する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20130109633A1 (https=) |
| EP (1) | EP2714012A1 (https=) |
| JP (1) | JP2014515371A (https=) |
| KR (1) | KR20140037877A (https=) |
| CN (1) | CN103687589A (https=) |
| AR (1) | AR086576A1 (https=) |
| BR (1) | BR112013030369A2 (https=) |
| CA (1) | CA2837174A1 (https=) |
| MX (1) | MX2013013760A (https=) |
| RU (1) | RU2013157188A (https=) |
| TW (1) | TW201300124A (https=) |
| WO (1) | WO2012162567A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109476704B (zh) * | 2016-04-08 | 2022-08-16 | 港大科桥有限公司 | 抗菌环脂肽 |
| US11667674B2 (en) | 2016-04-08 | 2023-06-06 | Versitech Limited | Antibacterial cyclic lipopeptides |
| US10647746B2 (en) | 2016-04-08 | 2020-05-12 | Versitech Limited | Antibacterial cyclic lipopeptides |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2394313A1 (en) * | 1999-12-15 | 2001-06-21 | Cubist Pharmaceuticals, Inc. | Novel lipopeptides as antibacterial agents |
| BR0112393A (pt) * | 2000-06-21 | 2003-07-08 | Internat Health Man Associates | Composições e processos para aperfeiçoamento de absorção oral de agentes antimicrobiais |
| NZ554405A (en) * | 2000-12-18 | 2009-04-30 | Cubist Pharm Inc | Method for preparing crystalline and crystal-like forms of purified lipopeptides |
| CA2587848A1 (en) * | 2004-11-12 | 2006-10-19 | Cubist Pharmaceuticals, Inc. | Antiinfective lipopeptides |
| US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| PL2379580T3 (pl) * | 2008-12-22 | 2014-05-30 | Merck Sharp & Dohme | Nowe środki przeciwbakteryjne do leczenia zakażeń wywołanych bakteriami Gram-dodatnimi |
| JP5491119B2 (ja) * | 2009-10-02 | 2014-05-14 | 日東電工株式会社 | 薬物含有微粒子を含む医薬組成物およびその製造方法 |
| CN102060914B (zh) * | 2009-11-13 | 2014-09-17 | 华东理工大学 | 海洋芽孢杆菌b-9987产脂肽类化合物及其制备和应用 |
| JP2013511522A (ja) * | 2009-11-23 | 2013-04-04 | イーグル・ファーマシューティカルズ・インコーポレーテッド | ダプトマイシン製剤 |
| SG10201407724YA (en) * | 2009-11-23 | 2014-12-30 | Cubist Pharm Inc | Daptomycin compositions and related methods |
-
2012
- 2012-05-24 MX MX2013013760A patent/MX2013013760A/es unknown
- 2012-05-24 CN CN201280025551.2A patent/CN103687589A/zh active Pending
- 2012-05-24 WO PCT/US2012/039476 patent/WO2012162567A1/en not_active Ceased
- 2012-05-24 JP JP2014512126A patent/JP2014515371A/ja active Pending
- 2012-05-24 BR BR112013030369A patent/BR112013030369A2/pt not_active IP Right Cessation
- 2012-05-24 KR KR1020137033768A patent/KR20140037877A/ko not_active Withdrawn
- 2012-05-24 CA CA2837174A patent/CA2837174A1/en not_active Abandoned
- 2012-05-24 EP EP12725988.5A patent/EP2714012A1/en not_active Withdrawn
- 2012-05-24 RU RU2013157188/15A patent/RU2013157188A/ru not_active Application Discontinuation
- 2012-05-25 TW TW101118841A patent/TW201300124A/zh unknown
- 2012-05-25 US US13/481,009 patent/US20130109633A1/en not_active Abandoned
- 2012-05-28 AR ARP120101868A patent/AR086576A1/es unknown
-
2013
- 2013-10-07 US US14/047,701 patent/US20140135273A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013511557A5 (https=) | ||
| KR102759845B1 (ko) | 2-｛4-[n-(5,6-디페닐피라진-2-일)-n-이소프로필아미노]부틸옥시｝-n-(메틸술포닐)아세트아미드를 함유하는 의약 조성물 | |
| JP2010534220A5 (https=) | ||
| KR20160142342A (ko) | 무정형 소포스부비르를 포함하는 고체 조성물 | |
| JP6942182B2 (ja) | カルグルミン酸を含有する非経口的薬剤配合物 | |
| CN102406622A (zh) | 一种托伐普坦的固体制剂 | |
| JP2014515371A5 (https=) | ||
| KR20110026311A (ko) | 엔테카비어의 신규한 염 | |
| JP2013544272A5 (https=) | ||
| TR201918102A1 (tr) | Bi̇r polar çözücüden i̇zole edi̇lmi̇ş amorf dapagli̇flozi̇n i̇çeren kati farmasöti̇k kompozi̇syon | |
| KR101446129B1 (ko) | 프란루카스트-함유 고형 제제의 제조방법 | |
| JP2016507535A5 (https=) | ||
| RU2013157188A (ru) | Композиции св-183,315 и относящиеся к ним способы | |
| CN102641240B (zh) | 一种苦柯胺b盐注射剂及其制备方法 | |
| CN103330933B (zh) | 含有米卡芬净或其盐的药物组合物 | |
| CN105853378A (zh) | 白藜芦醇烟酸酯纳米结晶速释胶囊制剂及其制备工艺 | |
| CN104093400A (zh) | 稳定的无定形雷特格韦钾盐预混料及其制备方法 | |
| CN103222964A (zh) | 一种奥利司他口服制剂及其制备方法 | |
| EP2925320B1 (en) | Novel method for improving the bioavailability of low aqueous solubility drugs | |
| JP2013543881A5 (https=) | ||
| ES2443968T3 (es) | Composiciones farmacéuticas de olmesartán | |
| KR20080099562A (ko) | 안정한 고체분산체 함유 약학조성물 | |
| KR20190064208A (ko) | 피마살탄을 포함하는 고체 분산체 | |
| EP2682105A1 (en) | Orally-disintegrating formulations of dexketoprofen | |
| WO2014007779A1 (en) | Orally-disintegrating formulations of dexketoprofen |